English	French	Notes	Complete/Exclude
GRADE/DIFFERENTIATION must be: 2 (Grade II)			
GRADE/DIFFERENTIATION must be: 4 (Grade IV)			
GRADE/DIFFERENTIATION = 			
HISTOLOGY must be leukemia or lymphoma (9590-9948)			
No TNM classification is available for LYMPHOMA			
SUMMARY STAGE cannot be blank			
No TNM classification is available for KAPOSI'S SAROMA			
EXTENSION may not be 00 (In situ)			
ICDO-TOPOGRAPHY = 			
PATHOLGIC EXTENSION = 			
PATHOLOGIC EXTENSION may only be coded for PROSTATE (C61.9) cases			
REGIONAL NODES POSITIVE = 			
LYMPH NODES may not be 0 (No lymph nodes)			
REGIONAL NODES EXAMINED = 99 (			
REGIONAL NODES POSITIVE must be 99 (Unk if nodes + or -, NA)			
HORMONE THERAPY = 			
Only BREAST and PROSTATE cases may be coded as receiving			
endocrine surgery or endocrine radiation			
Dead			
STATUS = 			
PLACE OF DEATH may not be blank			
CAUSE OF DEATH and STATE DEATH CERT may not both be blank			
White			
RACE 1 = 			
RACE 2 = 			
RACE 3 = 			
RACE 4 = 			
RACE 5 = 			
For race combinations RACE 1 may not be 'White'			
A specific race code may not occur more than once			
ONC*2.11*15			
Please install ONC*2.11*15 first. Installation Halted.			
ONC*2.11*20			
ONCO*2.11*20			
Please install ONC*2.11*20 first. Installation Halted.			
The Accession Year is not 2001.			
GI stromal sarcomas (8936) are being collected via paper data form.			
The Behavior Code is not 3 (Malignant).			
Invalid Histology code.			
Select section			
2001 Patient Care Evaluation Study of Gastric Cancers			
 PATIENT INFORMATION			
1400.6  1. CO-MORBID CONDITIONS (YES/NO).			
1571      CO-MORBID CONDITION #1.......			
1571.1      CO-MORBID CONDITION #2.......			
1571.2      CO-MORBID CONDITION #3.......			
1571.3      CO-MORBID CONDITION #4.......			
1571.4      CO-MORBID CONDITION #5.......			
1571.5      CO-MORBID CONDITION #6.......			
1500  2. PRIOR EXPOSURE TO RADIATION...			
1501  3. ALCOHOL CONSUMPTION...........			
1572  4. DURATION OF TOBACCO USE.......			
  5. MENOPAUSAL STATUS AND HORMONE			
      REPLACEMENT THERAPY..........: NA, male patient			
1502  5. MENOPAUSAL STATUS AND HORMONE                                                    REPLACEMENT THERAPY..........			
1503  6. H2 BLOCKER/PROTON PUMP                                                           INHIBITOR USE................			
1504  7. FAMILY HISTORY OF GASTRIC                                                        CANCER.......................			
1573  8. PERSONAL HISTORY OF OTHER                                                        INVASIVE MALIGNANCIES PRIOR                                                      TO THIS CANCER DIAGNOSIS....//^S X=PHDEF			
  9. ASSOCIATED BENIGN CONDTIONS:			
1505      H-PYLORI INFECTION...........			
1506      DUODENAL ULCER...............			
1507      GASTRIC ULCER................			
1509      PERNICIOUS ANEMIA............			
1510      POLYPS OF STOMACH............			
1511      POLYPOSIS OF SMALL OR LARGE                                                      BOWEL.......................			
1513      ATROPHIC GASTRITIS...........			
1514      GASTRIC METAPLASIA...........			
 10. H-PYLORI DRUGS GIVEN:			
1516      PROTON PUMP INHIBITORS.......			
1518      BISMUTH COMPOUNDS............			
1519 11. PRIOR INTRA-ABDOMINAL SURGERY.			
1520 12. YEAR OF PRIOR GASTRIC                                                            RESECTION....................			
     CO-MORBID CONDITIONS (YES/NO) equals 			
      CO-MORBID CONDITION #1 may not be blank			
      CO-MORBID CONDITION #1.......: 000.00 No co-morbidities			
      CO-MORBID CONDITION #2.......:			
      CO-MORBID CONDITION #3.......:			
      CO-MORBID CONDITION #4.......:			
      CO-MORBID CONDITION #5.......:			
      CO-MORBID CONDITION #6.......:			
      ANTIBIOTICS..................: H-pylori not present			
      PROTON PUMP INHIBITORS.......: H-pylori not present			
      H2 BLOCKERS..................: H-pylori not present			
      BISMUTH COMPOUNDS............: H-pylori not present			
 TUMOR INDENTIFICATION AND DIAGNOSIS			
1521 13. PERFORMANCE STATUS AT INITIAL                                                    DIAGNOSIS....................			
 14. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:			
1523      FEVER/NIGHT SWEATS...........			
1524      ACUTE HEMATEMESIS............			
1525      TRANSFUSIONS FOR BLOOD LOSS..			
1574      WEIGHT LOSS..................			
1528      EARLY SATIETY................			
 15. INITIAL STAGING STUDIES:			
1529      CT SCAN OF ABDOMEN...........			
1530      CT SCAN OF CHEST.............			
1531      CT PELVIS....................			
1533      GALLIUM SCAN.................			
1534      BIPEDAL LYMPHANGIOGRAM (LAG).			
1536      PET SCAN.....................			
1538      EUS (ENDOSCOPIC ULTRASOUND)..			
1539      PERITONEAL LAVAGE............			
 16. LABORATORY STUDIES:			
 17. GASTROSCOPIC EXAMINATION RESULTS:			
1545      CLINICAL/VISUAL EXAMINATION..			
1546 18. GASTRO-ESOPHAGEAL JUNCTION                                                       (SIEWART TYPE II/III)........			
 19. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:			
1547.3      LYMPH NODES..................			
1548 20. DATE OF FIRST TISSUE DIAGNOSIS			
 23. MOLECULAR MARKERS:			
1552 24. MITOTIC RATE..................			
1553 25. TUMOR NECROSIS................			
 26. PHENOTYPE MODALITY USED:			
1554      FLOW CYTOMETRY ON FRESH                                                          TISSUE......................			
1554.1      IMMUNOHISTOCHEMISTRY ON FROZEN                                                   TISSUE......................			
1554.2      IMMUNOHISTOCHEMISTRY ON                                                          PARAFIN EMBEDDED TISSUE.....			
1554.3      MOLECULAR GENETICS...........			
1554.4      POLYMERASE CHAIN REACTION                                                         TECHNIQUE..................			
1554.5      SOUTHERN BLOT TECHNIQUE......			
1555 27. ANN ARBOR STAGING.............			
 18. GASTRO-ESOPHAGEAL JUNCTION                                                       (SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)			
 21. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)			
 22. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)			
 24. MITOTIC RATE..................: NA (not leimyosarcoma)			
 25. TUMOR NECROSIS................: NA (not leimyosarcoma)			
      FLOW CYTOMETRY ON FRESH                                                          TISSUE......................: NA (not lymphoma)			
      IMMUNOCHEMISTRY ON FROZEN                                                        TISSUE......................: NA (not lymphoma)			
      IMMUNOHISTOCHEMISTRY ON                                                          PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)			
      MOLECULAR GENETICS...........: NA (not lymphoma)			
      POLYMERASE CHAIN REACTION                                                        TECHNIQUE...................: NA (not lymphoma)			
      SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)			
 27. ANN ARBOR STAGING.............: NA (not lymphoma)			
 FIRST COURSE OF TREATMENT - SURGERY			
1556 28. ADHERENCE OF RESECTED PRIMARY                                                    SPECIMEN.....................			
1557 29. MARGIN STATUS OF RESECTED                                                        PRIMARY SPECIMEN.............			
 30. EXTENT OF FREE MARGIN:			
1558      PROXIMAL MARGIN..............			
1558.1      DISTAL MARGIN................			
 31. RESECTION BEYOND STOMACH:			
1559.1      TRANVERSE COLON..............			
1559.5      ABDOMINAL WALL...............			
1559.6      ADRENAL GLAND................			
1559.8      SMALL INTESTINE..............			
1560      PERIGASTRIC LYMPH NODES......			
1560.1      COMMON HEPATIC LYMPH NODES...			
1560.2      CELIAC LYMPH NODES...........			
1560.3      SPLENIC LYMPH NODES..........			
1560.4      OTHER INTRA-ABDOMINAL NODES..			
1561 32. GROSSLY INVOLVED REGIONAL                                                        LYMPH NODES..................			
1562 33. HCT (HEMATOCRIT) VALUES BEFORE                                                   TRANSFUSION..................			
1563 34. TOTAL OPERATIVE BLOOD                                                            REPLACEMENT..................			
1564 35. INTRA/PERI-OPERATIVE DEATH....			
 36. COMPLICATIONS REQUIRING RE-OPERATION:			
1565      ANASTOMOTIC LEAK.............			
1565.1      STUMP LEAK...................			
1565.3      WOUND INFECTION..............			
1565.6      DEAD BOWEL...................			
1566 37. DATE OF SURGICAL DISCHARGE....			
 FIRST COURSE OF TREATMENT - RADIATION			
442 38. REGIONAL DOSE (cGy)...........			
1575 39. BOOST DOSE (cGy)..............			
1567 40. INTRA-OPERATIVE RADIATION                                                        THERAPY, DOSE (cGy)..........			
1568 41. CONCURRENT CHEMOTHERAPY.......			
 FIRST COURSE OF TREATMENT - CHEMOTHERAPY			
 42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:			
1569 43. INTRAPERITONEAL CHEMOTHERAPY..			
1577 44. CHEMOTHERAPEUTIC TOXICITY.....			
1578 45. CHEMOTHERAPY/SURGERY SEQUENCE.			
 FIRST COURSE OF TREATMENT - IMMUNOTHERAPY			
1570 46. ADMINSTRATION OF INTERFERON...			
 No surgery of the primary site was performed.			
 Proceed to data item 38.			
 No radiation therapy was administered.			
 Code data items 38-40 to 00000.			
 Do not answer data item 41, and proceed to data item 42.			
 38. REGIONAL DOSE (cGy)...........: 00000			
 39. BOOST DOSE (cGy)..............: Not administered			
 40. INTRA-OPERATIVE RADIATION			
      THERAPY, DOSE (cGy)..........: Not administered			
 41. CONCURRENT CHEMOTHERAPY.......:			
 No chemotherapy was administered.			
 Proceed to data item 46.			
 No immunotherapy administered.			
 Proceed to Treatment Complications.			
 TREATMENT COMPLICATIONS			
      COMPLICATION #1..............: 000.00 No complications			
 CASE REGISTRATION			
81 48. INITIALS OF CASE ABSTRACTOR...			
90 49. DATE CASE WAS ABSTRACTED......			
PATIENT INFORMATION			
 1. CO-MORBID CONDITIONS:			
     CO-MORBID CONDITION #1.......: 000.00 No co-morbidities			
     CO-MORBID CONDITION #1.......: 			
     CO-MORBID CONDITION #2.......: 			
     CO-MORBID CONDITION #3.......: 			
     CO-MORBID CONDITION #4.......: 			
     CO-MORBID CONDITION #5.......: 			
     CO-MORBID CONDITION #6.......: 			
 2. PRIOR EXPOSURE TO RADIATION...: 			
 3. ALCOHOL CONSUMPTION...........: 			
 4. DURATION OF TOBACCO USE.......: 			
 5. MENOPAUSAL STATUS AND HORMONE			
     REPLACEMENT THERAPY..........: 			
 6. H2/BLOCKER PROTON PUMP			
 7. FAMILY HISTORY OF GASTRIC			
 8. PERSONAL HISTORY OF OTHER			
     INVASIVE MALIGNANCIES PRIOR			
      TO THIS CANCER DIAGNOSIS....: 			
 9. ASSOCIATED BENIGN CONDITIONS:			
     H-PYLORI INECTION............: 			
     DUODENAL ULCER...............: 			
     GASTRIC ULCER................: 			
     PERNICIOUS ANEMIA............: 			
     POLYPS OF STOMACH............: 			
     POLYPOSIS OF SMALL OR LARGE			
     ATROPHIC GASTRITIS...........: 			
     GASTRIC METAPLASIA...........: 			
10. H-PYLORI DRUGS GIVEN:			
     PROTON PUMP INHIBITORS.......: 			
     BISMUTH COMPOUNDS............: 			
11. PRIOR INTRA-ABDOMINAL SURGERY.: 			
12. YEAR OF PRIOR GASTRIC			
Print Gastric Cancers PCE			
TUMOR IDENTIFICATION AND DIAGNOSIS			
13. PERFORMANCE STATUS AT INITIAL			
14. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:			
     FEVER/NIGHT SWEATS...........: 			
     ACUTE HEMATEMESIS............: 			
     TRANSFUSIONS FOR BLOOD LOSS..: 			
     WEIGHT LOSS..................: 			
     EARLY SATIETY................: 			
15. INITIAL STAGING STUDIES:			
     CT SCAN OF ABDOMEN...........: 			
     CT SCAN OF CHEST.............: 			
     CT PELVIS....................: 			
     GALLIUM SCAN.................: 			
     BIPEDAL LYMPHANGIOGRAM (LAG).: 			
     PET SCAN.....................: 			
     EUS (ENDOSCOPIC ULTRASOUND)..: 			
     PERITONEAL LAVAGE............: 			
16. LABORATORY STUDIES:			
17. GASTROSCOPIC EXAMINATION RESULTS:			
     CLINICAL/VISUAL EXAMINATION..: 			
18. GASTRO-ESOPHAGEAL JUNCTION			
     (SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)			
     (SIEWART TYPE II/III)........: 			
19. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:			
     LYMPH NODES..................: 			
20. DATE OF FIRST TISSUE DIAGNOSIS: 			
21. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)			
22. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)			
23. MOLECULAR MARKERS:			
24. MITOTIC RATE..................: NA (not leimyosarcoma)			
25. TUMOR NECROSIS................: NA (not leimyosarcoma)			
24. MITOTIC RATE..................: 			
25. TUMOR NECROSIS................: 			
26. PHENOTYPE MODALITY USED:			
     FLOW CYTOMETRY ON FRESH			
      TISSUE......................: NA (not lymphoma)			
     IMMUNOCHEMISTRY ON FROZEN			
     IMMUNOHISTOCHEMISTRY ON			
      PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)			
     MOLECULAR GENETICS...........: NA (not lymphoma)			
     POLYMERASE CHAIN REACTION			
      TECHNIQUE...................: NA (not lymphoma)			
     SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)			
27. ANN ARBOR STAGING.............: NA (not lymphoma)			
      FLOW CYTOMETRY ON FRESH			
      IMMUNOCHEMISTRY ON FROZEN			
      IMMUNOHISTOCHEMISTRY ON			
       PARAFIN EMBEDDED TISSUE.....: 			
      MOLECULAR GENETICS...........: 			
      POLYMERASE CHAIN REACTION			
      SOUTHERN BLOT TECHNIQUE......: 			
27. ANN ARBOR STAGING..............: 			
FIRST COURSE OF TREATMENT - SURGERY			
28. ADHERENCE OF RESECTED PRIMARY			
29. MARGIN STATUS OF RESECTED			
     PRIMARY SPECIMAN.............: 			
30. EXTENT OF FREE MARGIN:			
     PROXIMAL MARGIN..............: 			
     DISTAL MARGIN................: 			
31. RESECTION BEYOND STOMACH:			
     TRANVERSE COLON..............: 			
     ABDOMINAL WALL...............: 			
     ADRENAL GLAND................: 			
     SMALL INTESTINE..............: 			
     PERIGASTRIC LYMPH NODES......: 			
     COMMON HEPATIC LYMPH NODES...: 			
     CELIAC LYMPH NODES...........: 			
     SPLENIC LYMPH NODES..........: 			
     OTHER INTRA-ABDOMINAL NODES..: 			
32. GROSSLY INVOLVED REGIONAL			
33. HCT (HEMATOCRIT) VALUES BEFORE			
34. TOTAL OPERATIVE BLOOD			
35. INTRA/PERI-OPERATIVE DEATH....: 			
36. COMPLICATIONS REQUIRING RE-OPERATION:			
     ANASTOMOTIC LEAK.............: 			
     STUMP LEAK...................: 			
     WOUND INFECTION..............: 			
     DEAD BOWEL...................: 			
37. DATE OF SURGICAL DISCHARGE....: 			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
